Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $0.89 in the prior trading day, RAPT Therapeutics Inc (NASDAQ: RAPT) closed at $0.94, up 5.96%. In other words, the price has increased by $5.96 from its previous closing price. On the day, 0.72 million shares were traded.
Ratios:
Our goal is to gain a better understanding of RAPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On December 26, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.
Stifel Downgraded its Buy to Hold on November 13, 2024, whereas the target price for the stock was revised from $7 to $2.
Stock Price History:
Over the past 52 weeks, RAPT has reached a high of $4.60, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -3.72%, while the 200-Day Moving Average is calculated to be -33.51%.
Shares Statistics:
A total of 132.01M shares are outstanding, with a floating share count of 68.99M. Insiders hold about 47.85% of the company’s shares, while institutions hold 51.92% stake in the company.
Earnings Estimates
RAPT Therapeutics Inc (RAPT) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.25 and -$0.43 for the fiscal current year, implying an average EPS of -$0.35. EPS for the following year is -$1.53, with 6.0 analysts recommending between -$0.25 and -$7.01.
